These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 24283428)

  • 1. Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule.
    Hilkens PH; Planting AS; van der Burg ME; Moll JW; van Putten WL; Vecht CJ; van den Bent MJ
    Eur J Neurol; 1994 Sep; 1(1):45-50. PubMed ID: 24283428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity.
    van den Bent MJ; van Putten WL; Hilkens PH; de Wit R; van der Burg ME
    Eur J Cancer; 2002 Feb; 38(3):387-91. PubMed ID: 11818204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.
    Hilkens PH; van der Burg ME; Moll JW; Planting AS; van Putten WL; Vecht CJ; van den Bent MJ
    Eur J Cancer; 1995; 31A(5):678-81. PubMed ID: 7640038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.
    Hovestadt A; van der Burg ME; Verbiest HB; van Putten WL; Vecht CJ
    J Neurol; 1992 Mar; 239(3):143-6. PubMed ID: 1315383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
    Moore DH; Donnelly J; McGuire WP; Almadrones L; Cella DF; Herzog TJ; Waggoner SE;
    J Clin Oncol; 2003 Nov; 21(22):4207-13. PubMed ID: 14615449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
    Chaudhry V; Rowinsky EK; Sartorius SE; Donehower RC; Cornblath DR
    Ann Neurol; 1994 Mar; 35(3):304-11. PubMed ID: 7907208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity.
    Elderson A; Gerritsen van der Hoop R; Haanstra W; Neijt JP; Gispen WH; Jennekens FG
    J Neurol Sci; 1989 Nov; 93(2-3):167-74. PubMed ID: 2592981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial.
    Pace A; Giannarelli D; Galiè E; Savarese A; Carpano S; Della Giulia M; Pozzi A; Silvani A; Gaviani P; Scaioli V; Jandolo B; Bove L; Cognetti F
    Neurology; 2010 Mar; 74(9):762-6. PubMed ID: 20194916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats.
    Hamers FP; Brakkee JH; Cavalletti E; Tedeschi M; Marmonti L; Pezzoni G; Neijt JP; Gispen WH
    Cancer Res; 1993 Feb; 53(3):544-9. PubMed ID: 8425186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
    Roberts JA; Jenison EL; Kim K; Clarke-Pearson D; Langleben A
    Gynecol Oncol; 1997 Nov; 67(2):172-7. PubMed ID: 9367703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy.
    Argyriou AA; Polychronopoulos P; Koutras A; Xiros N; Petsas T; Argyriou K; Kalofonos HP; Chroni E
    Eur J Cancer Care (Engl); 2007 May; 16(3):231-7. PubMed ID: 17508942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative vibration perception threshold in assessing diabetic neuropathy: is the cut-off value lower for Indian subjects? [Q-VADIS Study].
    Ghosal S; Stephens J; Mukherjee A
    Diabetes Metab Syndr; 2012; 6(2):85-9. PubMed ID: 23153975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural history of diabetic peripheral neuropathy determined by a 12 year prospective study using vibration perception thresholds.
    Coppini DV; Wellmer A; Weng C; Young PJ; Anand P; Sönksen PH
    J Clin Neurosci; 2001 Nov; 8(6):520-4. PubMed ID: 11683597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer.
    van der Hoop RG; Vecht CJ; van der Burg ME; Elderson A; Boogerd W; Heimans JJ; Vries EP; van Houwelingen JC; Jennekens FG; Gispen WH
    N Engl J Med; 1990 Jan; 322(2):89-94. PubMed ID: 2152972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent neuropathy after treatment with cisplatin and oxaliplatin.
    Brouwers EE; Huitema AD; Boogerd W; Beijnen JH; Schellens JH
    Acta Oncol; 2009; 48(6):832-41. PubMed ID: 19308757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the new indicator test for sudomotor function (Neuropad) with the vibration perception threshold and the clinical examination in the diagnosis of peripheral neuropathy in subjects with type 2 diabetes.
    Papanas N; Papatheodorou K; Papazoglou D; Monastiriotis C; Christakidis D; Maltezos E
    Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):135-8. PubMed ID: 18095233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?
    Pace A; Nisticò C; Cuppone F; Bria E; Galiè E; Graziano G; Natoli G; Sperduti I; Jandolo B; Calabretta F; Tomao S; Terzoli E
    Clin Breast Cancer; 2007 Apr; 7(7):550-4. PubMed ID: 17509163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.